spacer
home > ebr > summer 2003 > mass-based fraction collection of crude synthetic peptides in analytical and preparative scale for cancer treatment
PUBLICATIONS
European Biopharmaceutical Review

Mass-Based Fraction Collection of Crude Synthetic Peptides in Analytical and Preparative Scale for cancer treatment

Synthetic peptides become more and more important as drug candidates in the treatment of a variety of diseases. A particular therapeutic focus for synthetic peptides is cancer treatment (1, 2). In order to keep pace with the growing number of newly synthesised peptides, peptide purification should not represent a bottleneck in the drug discovery process. Since the target masses of synthetic peptides are well known, mass-based fraction collection represents an efficient technique for their purification. In contrast to fraction triggering with less specific detectors, employing a mass selective detector only leads to the purification of the target mass in each run. Consequently, it is not necessary to pick out the compound of interest from a series of redundant fractions.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Ralf Moritz, Application Chemist at Agilent Technologies, and Nicola O'Reilly at Cancer Research UK
Ralf Moritz studied Chemistry at Gerhard Mercator University, Germany, before moving to McMaster University in Canada for a year in 1993.

He completed his PhD thesis at Robert Koch-Institute, Berlin in 2000 before undertaking research work at the Max Delbrück Centrum for Molecular Medicine, Berlin. Since 2001 Ralf has been an Application Chemist at Agilent Technologies, Germany.


Nicola O'Reilly received a BSc (Hons) in Chemistry from Southampton University in 1987. She then joined Cancer Research UK (then Imperial Cancer Research Fund), running the peptide synthesis laboratory.

In 1994 Nicola completed a master's degree in Biochemistry at King's College London. In October 1999 she set up a new 2D gel electrophoresis facility and in July 2000 she took over the ICRF Protein Isolation Service. After the formation of Cancer Research UK she opened up peptide synthesis and protein isolation to new Cancer Research UK clients.


spacer
Ralf Moritz
spacer
spacer
spacer
Nicola O'Reilly
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals welcomes Keensight Capital as majority shareholder


More info >>

White Papers

EU GDP Guidelines: Implications for Shipping Clinical Materials into the European Market

PCI Pharma Services

Recently, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) opened an investigation into a patient complaint of mold on paracetamol (acetaminophen) tablets (1). It discovered the product was shipped by sea from India to multiple companies in the UK at temperatures reaching up to 60 degrees Celsius. Labeling for paracetamol tablets typically states they should be kept below 30 degrees Celsius. In addition, MHRA discovered the humidity levels exceeded 80 percent during shipping, which is too high for the packaging that was used.
More info >>

 
Industry Events

World Vaccine Congress Europe

28-31 October 2019, Barcelona, Spain

The 20th annual World Vaccine Congress Europe is taking place 28-31 Oct in Barcelona. It’s the biggest and most established European vaccine event with over 250 speakers, 700+ senior vaccine attendees, hundreds of networking hours. It cover key topics across the complete vaccine value chain bringing together: • Government • big pharma • big biotech • SME Biotech • academia and the wider service provider community and their partners to discuss scientific, clinical and strategic advances and opportunities. The event has already confirmed over 200 speakers from Human Vaccine Project, OECD, CEPI, European Commission, FDA, WHO, OECD, NIH, GSK and many more… There is a Super Early Bird offer available – Find Out More www.terrapinn.com/WVCEU/EBR
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement